SPIREs: a new horizon for allergic disease treatment?
SPIREs: a new horizon for allergic disease treatment?
复制标题
SPIRE：过敏性疾病治疗的新视野？
DOI：
10.1586/1744666x.2015.1066673
复制
发表时间：
2015
影响因子：
4.4
通讯作者：
M. Worm
中科院分区：
文献类型：
--
作者：
M. Worm
过敏性疾病很常见，特异性免疫疗法提供了一种治疗方法。特异性免疫疗法有其局限性，因为使用的是完整的过敏原提取物。这些可能含有患者可能不敏感的蛋白质。所需的长期治疗（3-5 年）可能会引发 IgE 介导的严重过敏反应的潜在风险。一种新的有前景的治疗方法是应用短的合成 T 细胞肽。此类合成肽由长度为 13-17 个氨基酸的免疫调节表位 (SPIRE) 组成。来自室内研究的最新临床数据表明 SPIRE 具有良好的临床疗效和良好的耐受性。
Allergic diseases are common and specific immunotherapy provides a therapeutic approach. Specific immunotherapy has its limits, as whole allergen extracts are used. These may contain proteins that patients might not be sensitized to. A required long-term treatment (3–5 years) might activate a potential risk of IgE-mediated severe allergic reactions. A new promising therapeutic approach is to apply short synthetic T-cell peptides. Such synthetic peptides consist of immunoregulatory epitopes (SPIREs) that are 13–17 amino acids in length. Recent clinical data, derived from chamber studies, suggest a clinical efficacy with a good tolerability of SPIREs.